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Mutations in BRCA1 and BRCA2 cause tumor development in Hereditary Breast and 
Ovarian Cancer syndrome (HBOC) through accumulation of unrepaired DNA damage. 
Extensive research of BRCA1 and BRCA2 mutations has led to well-defined breast and ovarian 
cancer risks in individuals with HBOC. Previous studies have reported additional cancers 
associated with BRCA mutations; however, the type of cancer, magnitude of risk, and 
differences between sexes remains to be clarified. Ultimately, a consensus of additional cancer 
risks can aid in better recommendations for genetic testing and more effective screening and 
prevention guidelines.  
A retrospective chart review of MD Anderson Cancer Center patients identified 1081 
individuals with a BRCA mutation. A detailed cancer history for each person was collected and 
compared to the general population incidence rates reported by the CDC using standardized 
incidence ratios (SIR). Individuals with a BRCA2 mutation had significantly higher number of 
observed cases compared to expected cases for pancreatic cancer (SIR 21.7, 95% CI 13.1-
34.0, p value <0.001) in both men and women and prostate cancer in men (SIR 4.9, 95% CI 
2.0-10.1, p value = 0.002). Individuals with a BRCA1 mutation did not have a significant 
increase in cancers other than breast and ovarian; however, a trend in melanoma was 
observed in men and women. The results of this study uphold the current recommendations for 
HBOC screening of cancers other than breast and ovarian by the National Comprehensive 
Cancer Network.  
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Introduction 
BRCA1 and BRCA2 tumor suppressor genes repair DNA damage to prevent tumor 
development. Mutations in these genes predispose an individual to malignancy. The types of 
cancers associated with mutations in BRCA1 and BRCA2 have been studied continuously 
since their discovery in 1994 and 1995 respectively (Miki et al., 1994 & Wooster et al., 1995). 
Individuals with BRCA1 and BRCA2 mutations have a significantly increased lifetime risk for 
developing breast and ovarian cancer, as high as 84% and 39% respectively (Antoniou et al., 
2003; Chen et al., 2006; Easton et al., 1995; Ford et al., 1998). 
While the association of BRCA1 and BRCA2 mutations with breast and ovarian cancer 
risks is well-defined, the potential association of these mutations with other cancers is 
inconsistent. Prior studies have included families either at high risk for a BRCA mutation or 
combined BRCA1 and BRCA2 mutations carriers for analysis due to small numbers of 
individuals with BRCA mutations (Bermejo & Hemminki, 2004; Noh et al., 2012). These studies 
reported an increased incidence of cancers, other than breast and ovarian, in mutation carriers; 
however, these reports did not differentiate between BRCA1 and BRCA2 mutation carriers. 
Studies have been able to focus on BRCA1 or BRCA2 mutation carriers separately; 
however, the number of participants varies, with few studies containing more than 1000 
mutation carriers.  Ford et al (1994) found an increased risk for both sexes, while Thompson 
and Easton (2000) found an increased risk only in women and Moran et al (2012) reported 
BRCA1 mutations are not associated with an increased risk for other cancers. BRCA1 mutation 
carriers have a significantly increased risk of pancreatic, prostate, and colorectal cancer as 
reported in multiple studies (Brose et al, 2002; Ford et al, 1994; Iqbal et al., 2012; Phelan et al., 
2014; Thompson et al., 2002). BRCA1 mutations have been linked to increases in cervical, 
esophagus, liver, stomach, and uterine cancers; however, the increased risks were inconsistent 
and ranged from one to four fold (Brose et al, 2002; Ford et al, 1994; Moran et al, 2012; 
2 
 
Thompson et al., 2002). Known environmental risk factors associated with these cancers were 
not typically reported in these studies. 
The Breast Cancer Linkage Consortium (BCLC) reported BRCA2 mutations were 
associated with an increased cancer risk in both sexes (1999), while van Asperen found a 
significantly increased risk for men only (2005). The most commonly reported cancers with 
BRCA2 mutations include pancreas, prostate, and melanoma (BCLC, 1999; Easton et al., 
1997; Moran et al., 2012; Tai et al., 2007; van Asperen et al., 2005). Additional cancers 
reported in the BRCA2 spectrum include bone, buccal cavity and pharynx, esophagus, 
gallbladder and bile duct, laryngeal, ocular, male breast cancer, and stomach, although 
inconsistently across multiple studies. (BCLC, 1999; Easton et al., 1997; Moran et al., 2012; Tai 
et al., 2007; van Asperen et al., 2005). Environmental risk factors for these cancers were not 
regularly reported in these studies. 
The purpose of this study was to determine if cancers, other than breast and ovarian, 
were detected more often in BRCA mutation carriers than in the general population. The limited 
number of studies and variable results indicate a need for further research on the occurrence of 
non breast or ovarian cancers that are associated with BRCA1 and BRCA2 mutations. 
Ultimately, a consensus of additional cancer risk may aid in better recognition of at-risk families 
where genetic testing may be warranted and in more effective screening guidelines for the 
types of cancer these families are at risk to develop. 
 
Methods 
Study Population  
This study was approved by the MD Anderson Cancer Center Institutional Review 
Board and by The University of Texas Health Science Center at Houston Committee for the 
Protection of Human Subjects. Individuals who had received genetic counseling in the Clinical 
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Cancer Genetics clinics at the UT MD Anderson Cancer Center (MDACC) between 1997 and 
2013, and who had a confirmed BRCA1 or BRCA2 deleterious mutation, were eligible for this 
study. Individuals with variants suspected to be deleterious in BRCA1 or BRCA2 were included 
in this analysis because they are advised to follow the same high risk management guidelines 
as individuals with deleterious mutations in the clinical setting.  Medical record number, date of 
birth, gene, mutation designation, number of cancers, type of cancer, and age at diagnosis 
were obtained from a secure Progeny database comprised of data obtained during the genetic 
counseling session or from the patient’s medical record. Additional information on vital status, 
date of last contact with the institution, ethnicity, and selected risk factors were also obtained 
from the individual’s medical record. Selected risk factors included tobacco use, alcohol use, 
radiation exposure, body mass index, and history of mastectomy and/or bilateral salpingo-
oophorectomy (BSO). Information on personal cancer history was compared using information 
from both the medical record and the Progeny database to obtain the most current information.  
Individuals with two BRCA mutations, either deleterious or suspected deleterious, in the 
same gene were included in the analysis. Individuals with mutations in both the BRCA1 and 
BRCA2 genes, or with both a BRCA mutation and another known cancer-predisposing 
mutation or genetic condition were excluded from this analysis.  
Statistical Methods  
Cancer cases were counted for the total sample as well as for BRCA1 and BRCA2 
mutation carriers separately. The earliest age at diagnosis was used in the analysis for 
individuals that developed the same cancer more than once in their lifetime. Most cancers were 
analyzed independently. Similar or related cancers were grouped together for analysis. For 
example glioma, astrocytoma, and neuroblastoma were grouped into brain/central nervous 
system cancers. Ovarian cancer was also defined to include primary peritoneal and fallopian 
tube cancers. Within each cancer, or group of cancers, the data were stratified by sex and 
ethnicity.  
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We compared cancer incidence in our sample with the United States Cancer Statistics: 
1999-2010 Incidence and Morality Web-based Report (USCS) from the Centers of Disease 
Control and Prevention (CDC). Data from the USCS report combines the CDC’s National 
Program of Cancer Registries and National Cancer Institute’s Surveillance, Epidemiology, and 
End Results Program on cancer incidence in the United States population. The USCS report 
includes incidence data for 20 out of the 30 cancer types observed in our study population, 
including breast, ovarian, bladder, brain & CNS, cervical, colorectal, esophagus, Hodgkin 
lymphoma, non-Hodgkin lymphoma, kidney, leukemia, lung, melanoma, myeloma, oral cavity, 
ovarian, pancreas, prostate, stomach, thyroid, and uterine (USCS Working Group, 2013). 
Cancers without general population incidence rates in the USCS database were excluded from 
analysis. The excluded cancer types were male breast cancer, eye/orbit, lower GI, lymphoma, 
osteosarcoma, sarcoma, skin/nonmelanoma, unknown primary site, upper GI, and vulvar. The 
defined reference time frame for age-specific incidence rates in USCS was 2006-2010. 
Standardized incidence ratios (SIR) were calculated to compare number of cases of cancer in 
the sample population with general population data. The expected number of cancer cases was 
calculated from the number of individuals in the study sample multiplied by the general 
population cancer incidence rates. The expected and observed numbers of cases were 
calculated in 5 year intervals to accommodate different age-related incidence rates. SIRs for 
each cancer type, and associated confidence intervals (CIs), were calculated for the entire 
sample and for BRCA1 mutation carriers and BRCA2 mutation carriers separately. Data were 
also stratified by sex within the three groups. To account for multiple tests, we divided the 
standard p value of 0.05 for statistical significance by the number of cancer types; thus with 20 
tests a p value of <0.0025 was considered statistically significant.  
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Results  
We identified 1081 individuals with a deleterious mutation or variant suspected to be 
deleterious in BRCA1 or BRCA2 (Fig. 1). We excluded 3 who had both BRCA1 and BRCA2 
mutations, and 6 who had another genetic mutation or genetic condition in addition to a BRCA 
mutation, including neurofibromatosis (two individuals), Lynch syndrome, Turner syndrome, 
hereditary retinoblastoma, and 18p minus syndrome. Clinical characteristics of eligible 
individuals are reported in Figure 1. Demographic characteristics including sex and ethnicity 
are reported in Table 1. The mean age at date of last contact with MDACC was 49.3 years ( 
12.76, range 17-90). Of the 1072 individuals included in our sample, most were alive at the 
date of last contact (912, 85%). 
Figure 1. Distribution of mutations in BRCA genes in study population. 
 
* Includes 18 individuals with suspected deleterious variants 
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Table 1. Frequency of BRCA1 and BRCA2 mutations by sex and ethnicity in study 
population. 
All Subjects BRCA1 
n (%) 
BRCA2 
n (%) 
Total 
n 
Sex 
(p value=0.088*) 
Male 29 (46.77) 33 (53.23) 62 
Female 584 (57.82) 426 (42.18) 1010 
 Total 613 (57.18) 459 (42.82) 1072 
     
Ethnicity 
(p value=0.002†) 
Am Indian/Native 
Amer 
1 (33.33) 2 (66.67) 3 
Asian/Pacific Islander 22 (53.66) 19 (46.34) 41 
Black 43 (56.58) 33 (43.42) 76 
Hispanic 103 (72.03) 40 (27.97) 143 
White 440 (54.79) 363 (45.21) 803 
 Total (missing=6) 609 (57.13) 457 (42.87) 1066 
* p value from Chi-Square test; † p value from Fisher’s exact test 
 
We identified 1177 cancers in the 1072 mutation carriers comprising 30 different cancer 
types. After excluding duplicate cancers in same individual, the total number of cancer cases 
used in the analysis was reduced to 993 (Figure 2).  
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Figure 2. Demographics of cancers identified in study population. 
 
Comparison of the observed and expected cases identified four types of cancer with an 
increased SIR (Table 2). As expected, breast and ovarian cancers were observed at 
significantly increased rates in BRCA1 and BRCA2 mutation carriers. Individuals with a BRCA2 
mutation had a higher incidence of pancreatic cancer than expected in the general population 
(SIR 21.745, 95% CI 13.086-33.96, p<0.001). When males and females with BRCA2 mutations 
were analyzed separately the number of pancreatic cancers was significantly higher than 
expected in both sexes (males: SIR 82.559, 95% CI 39.524-151.84, p<0.001; females: SIR 
13.809, 95% CI 6.301-26.216, p<0.001). Prostate cancer was identified in significantly more 
men with a BRCA2 mutation than expected in the general population (SIR 4.890, 95% CI 
1.959-10.075, p=0.002).  
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Table 2. Observed and expected cancers for 1072 individuals (males and females) with 
BRCA mutations. 
Cancer Gene Obs Exp SIR 95% CI p value 
Bladder 
BRCA1 0 1.282 0 0-2.862 0.554 
BRCA2 1 1.373 0.728 0.010-4.053 0.791 
Brain & CNS 
BRCA1 3 1.268 2.367 0.849-8.078 0.269 
BRCA2 1 1.077 0.929 0.012-5.168 0.578 
Breast – female 
BRCA1 345 9.349 36.902 33.110-41.009 <0.001* 
BRCA2 246 8.885 27.688 24.336-31.373 <0.001* 
Cervical 
BRCA1 2 1.701 1.176 0.132-4.245 0.990 
BRCA2 6 1.361 4.410 1.61-9.599 0.006 
Colorectal 
BRCA1 6 3.800 1.579 0.577-3.437 0.367 
BRCA2 2 3.783 0.529 0.059-1.909 0.542 
Esophagus 
BRCA1 1 0.405 2.471 0.032-13.75 0.654 
BRCA2 0 0.422 0 0-8.694 0.677 
Hodgkin 
Lymphoma 
BRCA1 3 0.792 3.788 0.761-11.067 0.095 
BRCA2 0 0.634 0 0-5.787 0.929 
Non-Hodgkin 
Lymphoma 
BRCA1 0 2.114 0 0-1.735 0.237 
BRCA2 1 1.980 0.505 0.007-2.81 0.825 
Kidney 
BRCA1 2 1.806 1.107 0.124-3.998 0.925 
BRCA2 3 1.735 1.729 0.348-5.052 0.500 
Leukemia 
BRCA1 5 1.694 2.951 0.951-6.887 0.060 
BRCA2 3 1.493 2.010 0.404-5.872 0.376 
Lung 
BRCA1 2 4.547 0.440 0.049-1.588 0.335 
BRCA2 5 4.867 1.027 0.331-2.398 0.929 
Myeloma 
BRCA1 1 0.462 2.164 0.037-12.04 0.728 
BRCA2 0 0.477 0 0-7.683 0.747 
Oral Cavity 
BRCA1 2 1.362 1.468 0.165-5.30 0.784 
BRCA2 1 1.298 0.770 0.01-4.286 0.739 
Ovarian 
BRCA1 178 1.280 139.115 119.427-161.122 <0.001* 
BRCA2 87 1.1614 74.926 60.011-92.422 <0.001* 
Pancreas 
BRCA1 4 0.846 4.730 1.273-12.11 0.024 
BRCA2 19 0.874 21.745 13.086-33.96 <0.001* 
Prostate 
BRCA1 3 1.788 3.809 0.766-11.13 0.094 
BRCA2 7 1.432 4.890 1.959-10.075 0.002* 
Skin – 
Melanoma 
BRCA1 9 2.717 3.312 1.511-6.288 0.004 
BRCA2 2 2.456 0.814 0.091-2.94 0.887 
Stomach 
BRCA1 1 0.576 1.736 0.023-9.661 0.864 
BRCA2 1 0.570 1.755 0.023-9.763 0.858 
Thyroid 
BRCA1 5 2.736 1.828 0.589-4.265 0.283 
BRCA2 2 2.319 0.862 0.097-3.114 0.814 
Uterus 
BRCA1 4 2.872 1.393 0.375-3.566 0.645 
BRCA2 3 2.636 1.138 0.229-3.326 0.978 
* statistically significant difference between study population and general population (p<0.0025) 
Obs – observed cases; Exp – expected cases; SIR – standardized incidence ratio; CI – confidence 
interval 
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We observed a trend of increasing incidence of melanoma in BRCA1 mutation carriers 
(SIR 3.312, 95% CI 1.511-6.288, p=0.004) and of cervical cancer in BRCA2 mutation carriers 
(SIR 4.410, 95% CI 1.61-9.599, p=0.006), compared to general population data. The p values 
for melanoma and cervical cancer are approaching significance although they did not reach the 
conservative cutoff. The 95% confidence interval does not include 1.0 indicating that the 
general population and study sample are likely different populations. The increased incidence 
for these cancers was unlikely to occur by chance. 
Ten additional cancer types representing 64 total cases were identified in the study 
population but were not available in the CDC USCS database for statistical analysis (Table 3). 
Individuals with BRCA1 mutations made up 45.3% (29 cases) in this subset of cancers. 
Individuals with BRCA2 mutations comprised 54.7% (35 cases) in this subset of cancer types. 
Of note, all seven cases of male breast cancer occurred in men with BRCA2 mutations. Non-
melanoma skin cancer was the most common of these 10 types of cancer in BRCA1 and 
BRCA2 mutation carriers (18 and 19 cases, respectively). 
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Table 3. Description of additional cancers in remaining 64 cases of cancer that were not 
compared to the general population. 
Cancer 
BRCA1 
n (%) 
BRCA2 
n (%) 
Total 
n (%) 
Total 29 (100) 35 (100) 64 (100) 
Breast – Males 0 (0) 7 (20) 7 (10.9) 
Eye and Orbit 
1 (3.4) 
Uveal Melanoma 
1 (2.9) 
Ocular Melanoma 
2 (3.1) 
Lower GI 
2 (6.9) 
Anal Canal & Appendix 
0 2 (3.1) 
Lymphoma 1 (3.4) 2 (5.7) 3 (4.7) 
Osteosarcoma 0 (0) 1 (2.9) 1 (1.7) 
Sarcoma 2 (6.9) 1 (2.9) 3 (4.7) 
Skin – 
Nonmelanoma 
18 (62.1) 19 (54.3) 37 (57.8) 
Unknown Primary 
Site 
2 (6.9) 2 (5.7) 4 (6.3) 
Upper GI 
1 (3.4) 
Small Intestine 
1 (2.9) 
Cholangiocarcinoma 
2 (3.1) 
Vulvar 2 (6.9) 1 (2.9) 1 (1.7) 
 
Discussion 
This is one of the largest single institution studies of the cancer spectrum associated 
with BRCA1 and BRCA2 mutations. This study found an increased incidence in two cancers, 
other than breast and ovarian, in individuals with a BRCA mutation when stratified by gene and 
sex. The number of observed cases of pancreatic and prostate cancer was higher than 
expected in the general population for individuals with BRCA2 mutations. Individuals with a 
BRCA1 mutation did not have an increased incidence of any specific type of cancer. Our 
findings support the rationale for pancreatic and prostate cancer screening in individuals with a 
BRCA2 mutation. Furthermore, recent associations with additional cancers, including uterine 
and colorectal, were not evident in our study population. 
 In our analysis, the occurrence of pancreatic cancer in males and females with a 
BRCA2 mutation was nearly 22 times greater than expected in the study population. Other 
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studies have reported increased risks of a lesser magnitude for pancreatic cancer in men and 
women with BRCA2 mutations, including relative risk estimates ranging from 3.51-5.9 (BCLC, 
1999; Moran et al., 2012; van Asperen et al., 2005). The increased number of observed cases 
in this study above previous relative risks could be attributed to personal factors or a referral 
bias. Nearly half (8 of 19) individuals with pancreatic cancer had a history of smoking, which is 
a well documented risk factor for pancreatic cancer (Lowenfels & Maisonneuve, 2006). MDACC 
is a tertiary care center and individuals with complex cancer histories, poor prognosis, or 
multiple cancer diagnoses are often referred for treatment. Of note, the SIR used in this study 
is not relative risk. The SIR is an approximation of the relative risk; however, discrepancies can 
arise because the general population is composed of individuals with and without BRCA 
mutations.  Therefore, it is difficult to truly compare these statistical analyses.  
 Prostate cancer occurred approximately 5 times more frequently in males with BRCA2 
mutations than expected in the general population. The increased risk for prostate cancer in 
our study population is consistent with previous studies that have reported relative risk 
estimates ranging from 2.5-6.3 (BCLC, 1999; Easton et al., 1997; Moran et al., 2012; van 
Asperen et al., 2005). Our data confirms prior evidence that men with BRCA2 mutations are at 
an increased risk of prostate cancer. 
The incidence of melanoma in BRCA1 mutation carriers approached significance in this 
study (p = 0.004). We established a conservative level of statistical significance for this study 
because the study sample included individuals in multiple cancer groups rather than being 
mutually exclusive group comparisons. The 95% confidence interval suggests the increased 
incidence of melanoma in BRCA1 mutation carriers differentiates it from the general population. 
Melanoma has been associated with BRCA2 mutations in previous studies, although the risk 
with BRCA1 mutations is unclear (BCLC, 1999). Therefore this study suggests screening for 
melanoma in BRCA1 mutation carriers may be prudent. 
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The incidence of cervical cancer in BRCA2 mutation carriers also approached statistical 
significance in this study (p=0.006). The most common risk factor for cervical cancer is human 
papillomavirus infection (Schiffman et al., 2007).  We were unable to determine whether the 
cause of cervical cancer was viral or possibly associated with BRCA2 mutations. HPV status 
was available for three out of the six observed cervical cancer cases in women with a BRCA2 
mutation. All three tested negative for HPV; however, the test was performed 3 to 7 years after 
cancer diagnosis. Thus the tests may not have accurately identified HPV because the majority 
of HPV infections clear or become undetectable within two years of infection (Moscicki et al., 
1998). HPV status was not reported in the medical record for the remaining three individuals. It 
will be important to monitor the cancers with a trend of increasing incidence over time to 
determine if an association exists and what the magnitude of risk is for mutation carriers. 
BRCA mutations have been associated with uterine cancer risk, specifically more 
aggressive types (Shu et al., 2014). Women in the study had a BRCA1 or BRCA2 mutation and 
underwent a BSO, and their uterus remained intact. Four cases of high-risk uterine cancer 
were diagnosed out of 525 women during the study, which was significantly increased over the 
general population (SIR 14.48, p<0.001). In our overall sample, 7 cases of uterine cancer were 
observed compared to 5.507 expected. Three of the observed cases were classified as high 
risk (serous, clear cell, or sarcoma), three cases were low risk, and one case did not have 
pathology available for review. Thus, uterine cancer was not more prevalent in our study 
population than expected, although the occurrence of high risk uterine cancer was not 
specifically assessed.  
Male breast cancer was not able to be analyzed in this study because of insufficient 
general population data for comparison. Of note, all seven cases were observed in men with 
BRCA2 mutations which represent 21% of the men with a mutation in this gene. Our results 
appear to be consistent with prior studies that have found a stronger association with BRCA2 
mutations and male breast cancer compared to BRCA1 mutations (Tai et al., 2007).  
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Although our overall sample size of individuals with BRCA mutations is large in 
comparison to other published studies, the sample size remains a limitation for discovering 
small differences. Therefore a larger sample size is needed to assess the statistical 
significance of rare cancer in association with BRCA mutations. This might be accomplished by 
analyzing family histories for additional cancer or by collaborating with another large center. 
Another limitation is the use of general population incidence rates. The largest date range 
(2006-2010) in the USCS dataset was used; however, individuals in our sample developed 
cancer outside of this date range which required us to infer statistical associations. Also, 
cancers diagnosed at centers other than ours did not require pathological confirmation; thus 
there may be inaccurate reporting for some cancers. Because our study population was 
predominantly white (75%), the information learned from this study may not be generalizable 
across all ethnicities. 
 Our study observed more than the expected number of cases of pancreatic and 
prostate cancer in BRCA2 mutation carriers. A trend toward statistical significance in the 
incidence of melanoma with BRCA1 mutations was observed. The presence of male breast 
cancer exclusively with BRCA2 mutation carriers is consistent with previous studies. These 
findings support the current National Comprehensive Cancer Network Clinical Practice 
Guidelines in Oncology for Hereditary Breast and Ovarian Cancer syndrome management 
(NCCN, 2014). Recommendations or considerations for prostate cancer, male breast cancer, 
and melanoma screening have been included for individuals with BRCA1 or BRCA2 mutations. 
While the risk for pancreatic cancer has been acknowledged by NCCN, specific screening 
guidelines do not exist. Lack of effective procedures for early pancreatic cancer detection 
prevents the development of screening guidelines. The high rate of pancreatic cancer in men 
and women with BRCA2 mutations in this study further emphasizes the need for effective 
screening guidelines in this high-risk population.  
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